Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 5Phase 3 3Phase 4 2Phase 2/3 2Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Renal Cell 5Neuroendocrine Tumors 3Neoplasms 3Tuberous Sclerosis 2Kidney Neoplasms 2Breast Neoplasms 2Angiomyolipoma 2Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Skin Diseases 1Pancreatic Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Diseases 1

Interventions

Everolimus 2Cannabidiol 2Vigabatrin 1Doxycycline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Tuberous Sclerosis × Everolimus × Clear all
NCT05252585 2026-04-02

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Novartis

Phase 4 Active not recruiting
4 enrolled

Tuberous Sclerosis, Angiomyolipoma

NCT03525834 2021-09-09

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Novartis

Phase 4 Completed
40 enrolled 10 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡